Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Analysts at Leerink Partnrs upped their Q4 2024 earnings estimates for shares of Lexicon Pharmaceuticals in a note issued to investors on Thursday, November 14th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.09). The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.69) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals' FY2025 earnings at ($0.50) EPS and FY2026 earnings at ($0.25) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The company had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same quarter last year, the business earned ($0.21) earnings per share.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a "buy" rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an "outperform" rating in a research report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $6.00.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX traded down $0.06 during midday trading on Monday, reaching $0.91. The stock had a trading volume of 2,582,083 shares, compared to its average volume of 3,477,479. The firm's fifty day simple moving average is $1.61 and its 200-day simple moving average is $1.73. The stock has a market capitalization of $224.64 million, a P/E ratio of -1.30 and a beta of 1.24. Lexicon Pharmaceuticals has a 1-year low of $0.91 and a 1-year high of $3.73. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 11.49.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently made changes to their positions in LXRX. BNP Paribas Financial Markets increased its holdings in Lexicon Pharmaceuticals by 82.6% during the first quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company's stock worth $143,000 after buying an additional 26,859 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Lexicon Pharmaceuticals by 7.0% in the first quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company's stock valued at $15,363,000 after purchasing an additional 420,854 shares during the last quarter. Boulder Hill Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals in the first quarter valued at $615,000. Virtu Financial LLC acquired a new position in shares of Lexicon Pharmaceuticals in the first quarter valued at about $105,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in Lexicon Pharmaceuticals during the second quarter worth about $912,000. Institutional investors own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.